BACKGROUND: Cancer and Leukemia Group B (CALGB) Study 19802, a phase 2 study, evaluated whether dose intensification of daunorubicin and cytarabine could improve disease-free survival (DFS) in adults with acute lymphoblastic leukemia (ALL) and whether high-dose systemic and intrathecal methotrexate could replace cranial radiotherapy for central nervous system (CNS) prophylaxis. METHODS: One hundred sixty-one eligible, previously untreated patients ages 16 to 82 years (median age, 40 years) were enrolled, and 33 (20%) were aged ≥60 years. RESULTS: One hundred twenty-eight patients (80%) achieved complete remission (CR). Dose intensification of daunorubicin and cytarabine was feasible. At a median follow-up of 10.4 years for surviving patients, the 5-year DFS rate was 25% (95% confidence interval, 18%-33%), and the overall survival (OS) rate was 30% (95% confidence interval, 23%-37%). Patients aged <60 years who received the 80 mg/m(2) dose of daunorubicin had a DFS of 33% (95% confidence interval, 22%-44%) and an OS of 39% (95% confidence interval, 29%-49%) at 5 years. Eighty-four patients (52%) relapsed, including 9 patients (6%) who had isolated CNS relapses. The omission of cranial irradiation did not result in higher than historic CNS relapse rates. CONCLUSIONS: Intensive systemic, oral, and intrathecal methotrexate dosing permitted the omission of CNS irradiation in adult patients with ALL. This intensive approach using higher doses of daunorubicin and cytarabine failed to result in an overall improvement in DFS or OS compared with historic CALGB studies. Future therapeutic strategies for adults with ALL should be tailored to specific age and molecular genetic subsets.
BACKGROUND:Cancer and Leukemia Group B (CALGB) Study 19802, a phase 2 study, evaluated whether dose intensification of daunorubicin and cytarabine could improve disease-free survival (DFS) in adults with acute lymphoblastic leukemia (ALL) and whether high-dose systemic and intrathecal methotrexate could replace cranial radiotherapy for central nervous system (CNS) prophylaxis. METHODS: One hundred sixty-one eligible, previously untreated patients ages 16 to 82 years (median age, 40 years) were enrolled, and 33 (20%) were aged ≥60 years. RESULTS: One hundred twenty-eight patients (80%) achieved complete remission (CR). Dose intensification of daunorubicin and cytarabine was feasible. At a median follow-up of 10.4 years for surviving patients, the 5-year DFS rate was 25% (95% confidence interval, 18%-33%), and the overall survival (OS) rate was 30% (95% confidence interval, 23%-37%). Patients aged <60 years who received the 80 mg/m(2) dose of daunorubicin had a DFS of 33% (95% confidence interval, 22%-44%) and an OS of 39% (95% confidence interval, 29%-49%) at 5 years. Eighty-four patients (52%) relapsed, including 9 patients (6%) who had isolated CNS relapses. The omission of cranial irradiation did not result in higher than historic CNS relapse rates. CONCLUSIONS: Intensive systemic, oral, and intrathecal methotrexate dosing permitted the omission of CNS irradiation in adult patients with ALL. This intensive approach using higher doses of daunorubicin and cytarabine failed to result in an overall improvement in DFS or OS compared with historic CALGB studies. Future therapeutic strategies for adults with ALL should be tailored to specific age and molecular genetic subsets.
Authors: N Gökbuget; D Hoelzer; R Arnold; A Böhme; C R Bartram; M Freund; A Ganser; M Kneba; W Langer; T Lipp; W D Ludwig; G Maschmeyer; H Rieder; E Thiel; A Weiss; D Messerer Journal: Hematol Oncol Clin North Am Date: 2000-12 Impact factor: 3.722
Authors: M Schrappe; A Reiter; W D Ludwig; J Harbott; M Zimmermann; W Hiddemann; C Niemeyer; G Henze; A Feldges; F Zintl; B Kornhuber; J Ritter; K Welte; H Gadner; H Riehm Journal: Blood Date: 2000-06-01 Impact factor: 22.113
Authors: N Winick; J J Shuster; W P Bowman; M Borowitz; A Farrow; D Jacaruso; G R Buchanan; B A Kamen Journal: J Clin Oncol Date: 1996-10 Impact factor: 44.544
Authors: R Bassan; E Pogliani; T Lerede; P Fabris; G Rossi; S Morandi; P Casula; G Lambertenghi-Deliliers; M Vespignani; T Izzi; P Coser; G Corneo; T Barbui Journal: Haematologica Date: 1999-12 Impact factor: 9.941
Authors: W K Hofmann; G Seipelt; S Langenhan; R Reutzel; D Schott; O Schoeffski; H J Illiger; F Hartmann; L Balleisen; A Franke; F Fiedler; C Huber; H Rasche; L Bergmann; A Ganser; C Pott; R Pasold; C Rudolph; O G Ottmann; N Gökbuget; D Hoelzer Journal: Ann Hematol Date: 2002-10-17 Impact factor: 3.673
Authors: R Bassan; A Z Rohatiner; T Lerede; E Di Bona; A Rambaldi; E Pogliani; G Rossi; P Fabris; S Morandi; P Casula; M Carter; G Lambertenghi-Deliliers; T A Lister; T Barbui Journal: Hematol J Date: 2000
Authors: W A Kamps; J P M Bökkerink; F G A J Hakvoort-Cammel; A J P Veerman; R S Weening; E R van Wering; J F van Weerden; J Hermans; R Slater; E van den Berg; W G Kroes; A van der Does-van den Berg Journal: Leukemia Date: 2002-06 Impact factor: 11.528
Authors: Nelli Bejanyan; Mei-Jie Zhang; Hai-Lin Wang; Aleksandr Lazaryan; Marcos de Lima; David I Marks; Brenda M Sandmaier; Veronika Bachanova; Jacob Rowe; Martin Tallman; Partow Kebriaei; Mohamed Kharfan-Dabaja; Robert Peter Gale; Hillard M Lazarus; Celalettin Ustun; Edward Copelan; Betty Ky Hamilton; Gary Schiller; William Hogan; Shahrukh Hashmi; Matthew Seftel; Christopher G Kanakry; Richard F Olsson; Rodrigo Martino; Wael Saber; H Jean Khoury; Daniel J Weisdorf Journal: Biol Blood Marrow Transplant Date: 2017-12-21 Impact factor: 5.742
Authors: Kathryn G Roberts; Zhaohui Gu; Debbie Payne-Turner; Kelly McCastlain; Richard C Harvey; I-Ming Chen; Deqing Pei; Ilaria Iacobucci; Marcus Valentine; Stanley B Pounds; Lei Shi; Yongjin Li; Jinghui Zhang; Cheng Cheng; Alessandro Rambaldi; Manuela Tosi; Orietta Spinelli; Jerald P Radich; Mark D Minden; Jacob M Rowe; Selina Luger; Mark R Litzow; Martin S Tallman; Peter H Wiernik; Ravi Bhatia; Ibrahim Aldoss; Jessica Kohlschmidt; Krzysztof Mrózek; Guido Marcucci; Clara D Bloomfield; Wendy Stock; Stephen Kornblau; Hagop M Kantarjian; Marina Konopleva; Elisabeth Paietta; Cheryl L Willman; Charles G Mullighan Journal: J Clin Oncol Date: 2016-11-21 Impact factor: 44.544
Authors: N Toft; H Birgens; J Abrahamsson; L Griškevičius; H Hallböök; M Heyman; T W Klausen; Ó G Jónsson; K Palk; K Pruunsild; P Quist-Paulsen; G Vaitkeviciene; K Vettenranta; A Åsberg; T L Frandsen; H V Marquart; H O Madsen; U Norén-Nyström; K Schmiegelow Journal: Leukemia Date: 2017-08-18 Impact factor: 11.528
Authors: W Stock; B Diouf; K R Crews; D Pei; C Cheng; K Laumann; S J Mandrekar; S Luger; A Advani; R M Stone; R A Larson; W E Evans Journal: Clin Pharmacol Ther Date: 2016-11-16 Impact factor: 6.875